Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Fecal Microbiota Transplantation with Nivolumab in Advanced Solid Cancers Refractory to Anti-PD-(L)1
KCT0007574Phase 2Not yet recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Nonhematologic neoplasms, sponsored by Ono Pharmaceutical. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on KCT0007574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007574.